---
provider: openscientist
model: openscientist-autonomous
cached: false
start_time: '2026-10-25T05:45:14.973589'
end_time: '2026-10-25T06:04:07.300959'
duration_seconds: 1132.33
template_file: templates/disease_pathophysiology_research.md
template_sha: "f452f0a9c7e3536175154b9683c45663f686f283"
template_variables:
  disease_name: Oocyte/Zygote/Embryo Maturation Arrest 24
  mondo_id: MONDO:0979232
  category: Mendelian
  causal_genes: TUBA1C
  omim_id: OMIM:621232
  synonyms: OZEMA24; oocyte maturation defect 24; OOMD24; TUBA1C-related female infertility;
    TUBA1C-related recurrent preimplantation embryo arrest
provider_config:
  timeout: 3600
  max_retries: 3
  parameters:
    allowed_domains: []
    max_iterations: 5
    use_hypotheses: false
    investigation_mode: autonomous
    poll_interval: 30
    timeout: 3600
    save_artifacts: true
    artifact_max_bytes: 5242880
citation_count: 5
reference_validation:
  total_references: 7
  verified: 7
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  relevance_assessed: 7
  on_topic: 7
  validator_version: 0.4.0
term_validation:
  total_terms: 22
  verified: 20
  not_found: 0
  obsolete: 0
  unverifiable: 2
  confabulation_rate: 0.0
  labels_checked: 17
  labels_matching: 12
  labels_mismatched: 3
  mislabelled_terms:
  - term_id: HP:0030359
    reported_labels:
    - Abnormality of female reproductive system
    ontology_label: Squamous cell lung carcinoma
  - term_id: CHEBI:36976
    reported_labels:
    - nucleotide, GTP context of tubulin
    ontology_label: nucleotide
  - term_id: UBERON:0000995
    reported_labels:
    - "uterus \u2014 downstream implantation context"
    ontology_label: uterus
  labels_variant: 2
  unresolvable_prefixes:
  - OMIM
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
artifact_count: 2
artifact_sources:
  openscientist_artifacts_zip: 2
artifacts:
- filename: final_report.html
  path: Oocyte_Zygote_Embryo_Maturation_Arrest_24-deep-research-openscientist_artifacts/final_report.html
  media_type: text/html
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
- filename: final_report.pdf
  path: Oocyte_Zygote_Embryo_Maturation_Arrest_24-deep-research-openscientist_artifacts/final_report.pdf
  media_type: application/pdf
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Oocyte/Zygote/Embryo Maturation Arrest 24
- **MONDO ID:** MONDO:0979232 (if available)
- **Causal gene(s):** TUBA1C
- **OMIM:** OMIM:621232
- **Synonyms:** OZEMA24; oocyte maturation defect 24; OOMD24; TUBA1C-related female infertility; TUBA1C-related recurrent preimplantation embryo arrest
- **Category:** Mendelian

Many disease names are serial numbers ("... autosomal dominant 64", "... 26") that
do not say which gene the disease is about, and a similarly named disease with a
different gene is easy to research by mistake. Research the disease with the MONDO
ID and causal gene given above, and name its causal gene in your first paragraph.
If the name seems to point to a different gene or OMIM entry, follow the
identifiers above.

## Research Objectives

Please provide a comprehensive research report on **Oocyte/Zygote/Embryo Maturation Arrest 24** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# Oocyte/Zygote/Embryo Maturation Arrest 24 (OZEMA24 / OOMD24) — Comprehensive Disease Report

**Disease:** Oocyte/Zygote/Embryo Maturation Arrest 24
**Causal gene:** **TUBA1C** (tubulin alpha 1c; α-tubulin isotype; HGNC:20768; NCBI Gene 84790; Ensembl ENSG00000167553; UniProt Q9BQE3)
**MONDO:** MONDO:0979232 · **OMIM:** 621232
**Synonyms:** OZEMA24; OOMD24; oocyte maturation defect 24; TUBA1C-related female infertility; TUBA1C-related recurrent preimplantation embryo arrest (RPEA/PREA)
**Category:** Mendelian, autosomal recessive

---

## Summary

Oocyte/Zygote/Embryo Maturation Arrest 24 (OZEMA24, also OOMD24) is an **autosomal-recessive female-infertility disorder caused by biallelic loss-of-function variants in the α-tubulin isotype gene TUBA1C**. It is distinct from the β-tubulin isotype *TUBB8* (the prototypical and most common tubulin cause of oocyte maturation arrest) and from the α-tubulin gene *TUBA4A* (reported in the same cohort). The disease was established by whole-exome sequencing of a recurrent preimplantation embryo arrest (RPEA/PREA) cohort, in which two homozygous truncating TUBA1C alleles — **p.Gln358Ter** (nonsense) and **p.Asp444Metfs\*42** (frameshift) — were identified as disease-causing (Hu et al., *J Med Genet* 2024, [PMID: 39209701](https://pubmed.ncbi.nlm.nih.gov/39209701/)). Both variants produce truncated, non-functional α-tubulin and cause spindle assembly defects in functional assays, consistent with the recessive inheritance pattern expected for a loss-of-function mechanism.

Mechanistically, TUBA1C encodes an α-tubulin that heterodimerizes with β-tubulin to form the αβ-tubulin building block of microtubules. Loss of functional TUBA1C depletes the pool of assembly-competent αβ-tubulin available during the meiotic and early mitotic divisions, impairing **meiotic/mitotic spindle assembly** and faithful chromosome segregation in the oocyte and cleavage-stage embryo. The downstream consequence is **recurrent arrest of the preimplantation embryo**, failure of assisted reproductive technology (ART) cycles, and female sterility. This mechanism closely parallels the far better-characterized β-tubulin isotype **TUBB8**, whose pathogenic variants deplete the αβ-tubulin dimer pool and disrupt microtubule nucleation, plus-end tracking (EB1), CKAP5/TACC3 interactions, and the Ran-GTP spindle-assembly pathway during oocyte meiosis.

OZEMA24 is a newly delineated, ultra-rare Mendelian disorder; precise prevalence is unknown and it is identified almost exclusively in infertility clinics through genetic testing of women with repeated ART failure. There is **no corrective therapy**. Management centers on molecular diagnosis (WES or infertility gene panels), genetic counseling for consanguineous/carrier couples, and achieving pregnancy through **donor-oocyte IVF**. Because the defect is intrinsic to the oocyte/early embryo, the patient's own oocytes are not expected to be rescuable by standard clinical means; experimental cRNA/mRNA rescue approaches demonstrated for other tubulinopathy genes remain preclinical.

---

## Key Findings

### Finding 1 — Biallelic TUBA1C loss-of-function variants cause recurrent preimplantation embryo arrest (OZEMA24/OOMD24)

Whole-exome sequencing of a recurrent preimplantation embryo arrest (RPEA/PREA) cohort identified **two homozygous TUBA1C variants — p.Gln358Ter (nonsense) and p.Asp444Metfs\*42 (frameshift)** — as disease-causing. Both are predicted loss-of-function (truncating) variants, consistent with autosomal recessive inheritance. In vitro functional assays showed the variants cause spindle assembly defects of varying degree. The same study (Hu et al., *J Med Genet* 2024) also implicated the related α-tubulin isotype **TUBA4A** (p.Arg339Cys, p.Tyr440Ter), underscoring the broader importance of α-tubulin isotypes in preimplantation development.

The authors state directly: *"Four homozygous variants were identified in the PREA cohort: two of TUBA1C (p.Gln358Ter and p.Asp444Metfs\*42) and two of TUBA4A (p.Arg339Cys and p.Tyr440Ter). These variants cause varying degrees of spindle assembly defects."* They further conclude: *"Our findings identified TUBA1C as a novel genetic marker and expanded the genetic and phenotypic spectrum of TUBA4A in female infertility and RPEA, which altogether highlighted the importance of α-tubulin isotypes in preimplantation embryonic development."* ([PMID: 39209701](https://pubmed.ncbi.nlm.nih.gov/39209701/))

**Evidence type:** Human clinical (WES cohort) + in vitro functional validation.

### Finding 2 — TUBA1C is missense-constrained but tolerant of heterozygous loss-of-function, consistent with recessive disease

Population constraint metrics from gnomAD (GRCh38; ENSG00000167553 / ENST00000301072) show a gene that is strongly protected against amino-acid-changing variation but tolerant of a single loss-of-function allele:

| Metric | Value | Interpretation |
|---|---|---|
| pLI | 0.055 | Not haploinsufficient (LoF tolerated in heterozygous state) |
| oe_lof (LOEUF) | 0.458 (90% CI 0.31–0.70) | Moderate LoF constraint |
| LoF-Z | 2.72 | Some selection against LoF |
| Observed vs expected LoF | 16 vs 34.9 | Fewer LoF than expected, but present |
| missense-Z | 4.55 (oe_mis = 0.56) | **Strong** selection against missense |

The high missense-Z (4.55) indicates strong purifying selection against amino-acid substitutions, while the moderate pLI/LOEUF indicates that **heterozygous** loss-of-function is tolerated in the general population. This genetic architecture is fully consistent with an **autosomal-recessive** disease in which carriers are healthy and only biallelic (homozygous) LoF produces the phenotype — exactly matching the two homozygous disease alleles reported.

**Evidence type:** Computational / population genetics (gnomAD).

### Finding 3 — Mechanism: TUBA1C loss impairs meiotic/mitotic spindle assembly causing preimplantation arrest

Functional validation in the index study used Sanger sequencing, bioinformatic prediction, in vitro functional assays, and single-cell RNA-sequencing of arrested embryos, and showed that TUBA1C/TUBA4A variants cause *"varying degrees of spindle assembly defects."* The authors note: *"Functional characterisations of the identified candidate disease-causing variants were validated using Sanger sequencing, bioinformatics, in vitro functional analyses and single-cell RNA-sequencing of arrested embryos,"* and define the clinical endpoint: *"Recurrent preimplantation embryo developmental arrest (RPEA) is the most common phenotype in assisted reproductive technology treatment failure associated with identified genetic abnormalities."* ([PMID: 39209701](https://pubmed.ncbi.nlm.nih.gov/39209701/))

The mechanism is strongly supported by the analogous β-tubulin isotype **TUBB8**. In TUBB8 tubulinopathies, pathogenic variants reduce the α/β-tubulin dimer pool and impair microtubule nucleation, EB1 plus-end tracking, and CKAP5/TACC3 interactions, attenuating the Ran-GTP pathway during meiosis (Luo et al., 2025, [PMID: 39834092](https://pubmed.ncbi.nlm.nih.gov/39834092/); Feng et al., 2016, [PMID: 27273344](https://pubmed.ncbi.nlm.nih.gov/27273344/)). Because α- and β-tubulin function as an obligate heterodimer, loss of an expressed α-tubulin isotype is mechanistically expected to produce the same class of spindle defect.

**Evidence type:** Human clinical + in vitro + single-cell transcriptomics (TUBA1C); model organism + proteomics (TUBB8 parallel).

### Finding 4 — ClinVar classifies both TUBA1C disease alleles as Pathogenic; most other TUBA1C variants are VUS

A ClinVar query (NCBI E-utilities, 2026) returned 59 TUBA1C records. The two OZEMA24 disease alleles are recorded and classified **Pathogenic**: **"Q358\*"** (p.Gln358Ter) and **"TUBA1C, 1-BP DEL, NT1330"** (the c.1330-region 1-bp deletion corresponding to p.Asp444Metfs\*42), both OMIM-sourced allelic variants (OMIM:621232). The reference transcript is **NM_032704.5**. The large majority of other TUBA1C ClinVar entries (e.g., p.Arg320His, p.Arg214Cys, p.Thr334Ala) are **Uncertain significance (VUS)**; a small number of synonymous/intronic variants are Likely benign.

**Evidence type:** Curated variant database (ClinVar/OMIM).

---

## Full Section-by-Section Report

### 1. Disease Information

**Overview.** OZEMA24 is a Mendelian female-infertility disorder in which oocytes and/or early embryos arrest during the preimplantation window owing to defective spindle assembly. Affected women typically present with primary infertility and repeated failure of assisted reproduction, with embryos arresting before the blastocyst stage (recurrent preimplantation embryo developmental arrest, RPEA/PREA).

**Key identifiers.**
- **OMIM:** 621232
- **MONDO:** MONDO:0979232
- **Gene:** TUBA1C (HGNC:20768; NCBI Gene 84790; Ensembl ENSG00000167553; UniProt Q9BQE3); reference transcript NM_032704.5
- **Orphanet / ICD-10 / ICD-11 / MeSH:** No dedicated disease-specific code identified for OZEMA24; it falls under broad female-infertility categories (e.g., ICD-10 N97.x female infertility; ICD-11 GA31). *Not available at the disease-specific level.*

**Synonyms.** OZEMA24; OOMD24; oocyte maturation defect 24; TUBA1C-related female infertility; TUBA1C-related recurrent preimplantation embryo arrest.

**Information source.** Derived primarily from **aggregated disease-level resources** (OMIM, ClinVar) built on a small number of **individual patients** reported in the primary WES cohort (Hu et al. 2024).

### 2. Etiology

**Causal factors.** Purely **genetic** — biallelic (homozygous) loss-of-function variants in TUBA1C. No environmental, infectious, or acquired cause is implicated.

**Genetic risk factors.** The causal variants are **p.Gln358Ter** (nonsense) and **p.Asp444Metfs\*42** (frameshift), both truncating/LoF, both reported in the homozygous state. **Consanguinity** is a key risk context for homozygous recessive alleles. Carriers (heterozygotes) are unaffected (Finding 2).

**Environmental risk factors.** None established. General oocyte-quality modifiers (advanced maternal age, oxidative stress) are not the cause here, though they could theoretically aggravate an already compromised spindle. *Not demonstrated for this disease.*

**Protective factors.** Not applicable beyond the trivial observation that a wild-type TUBA1C allele is protective (recessive disease; heterozygotes unaffected). No pharmacologic or lifestyle protective factor is known.

**Gene–environment interactions.** None reported; the phenotype appears to be fully genetically determined given biallelic LoF.

### 3. Phenotypes

The phenotype is essentially **reproductive and cellular**, with no somatic disease (carriers and patients are otherwise healthy).

| Phenotype | Type | Onset | Severity | Frequency | Suggested HPO |
|---|---|---|---|---|---|
| Female infertility | Clinical sign | Reproductive age | Severe | Core/obligate | HP:0008222 (Female infertility) |
| Recurrent preimplantation embryo arrest | Lab/clinical (ART) | At ART attempts | Severe | Core | — (no precise HPO; cf. abnormal embryonic development) |
| Oocyte/zygote maturation arrest | Lab (cellular) | At ART attempts | Variable | Characteristic | HP:0030359 (Abnormality of female reproductive system) |
| Spindle assembly defect (oocyte/embryo) | Lab abnormality (cellular) | Meiosis/early mitosis | Variable | Core mechanism | — |

**Characteristics.** Onset is at reproductive age and manifests only when pregnancy is attempted. Progression is **stable/non-progressive** (a fixed functional defect, not a degenerative process). There are no systemic, neurological, or developmental features — distinguishing it from somatic tubulinopathies (which involve brain malformations). **Quality-of-life impact** is substantial but confined to the reproductive domain: infertility, psychological distress, and repeated unsuccessful ART cycles.

### 4. Genetic/Molecular Information

- **Causal gene:** TUBA1C (OMIM 621232; HGNC:20768). Encodes an α-tubulin isotype that dimerizes with β-tubulin.
- **Pathogenic variants (ClinVar Pathogenic; NM_032704.5):**

| Variant (protein) | Type | Zygosity reported | ClinVar | Functional consequence |
|---|---|---|---|---|
| p.Gln358Ter (Q358\*) | Nonsense (truncating) | Homozygous | Pathogenic | Loss of function; spindle assembly defect |
| p.Asp444Metfs\*42 (1-bp del, NT1330 region) | Frameshift (truncating) | Homozygous | Pathogenic | Loss of function; spindle assembly defect |

- **Variant classification:** Both disease alleles **Pathogenic**; most other TUBA1C ClinVar entries are **VUS** (e.g., p.Arg320His, p.Arg214Cys, p.Thr334Ala); a few synonymous/intronic are Likely benign (Finding 4).
- **Allele frequency:** Disease alleles are ultra-rare/absent from population databases; gnomAD shows TUBA1C LoF is depleted (obs 16 vs exp 34.9) and missense strongly constrained (Finding 2).
- **Origin:** **Germline**, biallelic. No somatic involvement.
- **Functional consequence:** **Loss of function** (truncating). Recessive mechanism (not dominant-negative), distinguishing it from many TUBB8 missense variants which can act dominantly.
- **Modifier genes:** None established; the related isotype TUBA4A causes an overlapping RPEA phenotype through independent variants.
- **Epigenetic information / chromosomal abnormalities:** None reported; a single-gene point-mutation/indel disorder with no aneuploidy or structural chromosome change as the cause (though downstream embryonic aneuploidy may arise from spindle failure).

### 5. Environmental Information

No **environmental**, **lifestyle**, or **infectious** factors are implicated. OZEMA24 is a monogenic disorder; these categories are **not applicable**.

### 6. Mechanism / Pathophysiology

**Ordered causal chain (initiating lesion → clinical manifestation):**

1. **Biallelic truncating variant in TUBA1C** (p.Gln358Ter or p.Asp444Metfs\*42) **leads to** loss of functional/full-length TUBA1C α-tubulin protein (likely via truncation and/or nonsense-mediated decay). *[Demonstrated: WES + variant annotation.]*
2. Loss of functional TUBA1C **results in** a reduced pool of assembly-competent **αβ-tubulin heterodimer** in the oocyte/early embryo (α-tubulin is an obligate heterodimer partner of β-tubulin). *[Inferred from tubulin biology; directly demonstrated for the paralog TUBB8.]*
3. Depleted/defective tubulin dimer **impairs microtubule nucleation and dynamics**, which **disrupts meiotic and early mitotic spindle assembly**. *[Demonstrated: "varying degrees of spindle assembly defects," in vitro assays.]*
4. Defective spindle assembly **leads to** failure of accurate chromosome segregation / cytokinesis during oocyte maturation and the first embryonic divisions. *[Inferred from spindle defect; parallels TUBB8.]*
5. This **results in** oocyte maturation arrest, zygote/cleavage arrest, and **recurrent preimplantation embryo developmental arrest (RPEA)**. *[Demonstrated: cohort phenotype + scRNA-seq of arrested embryos.]*
6. RPEA **leads to** repeated ART failure and **female infertility/sterility** — the clinical manifestation. *[Demonstrated: clinical phenotype.]*

```
TUBA1C biallelic LoF (Q358*, D444Mfs*42)
        │  leads to
        ▼
Loss of functional α-tubulin (TUBA1C)
        │  results in
        ▼
↓ assembly-competent αβ-tubulin dimer pool
        │  impairs
        ▼
Microtubule nucleation / spindle assembly defect ──┐ (parallels TUBB8:
        │  leads to                                  │  ↓EB1, ↓CKAP5/TACC3,
        ▼                                            │  attenuated Ran-GTP)
Chromosome mis-segregation / division failure ◄──────┘
        │  results in
        ▼
Oocyte/zygote maturation & preimplantation embryo ARREST
        │  leads to
        ▼
Recurrent ART failure → FEMALE INFERTILITY
```

**Molecular pathways / cellular processes.** Microtubule cytoskeleton organization; meiotic and mitotic spindle assembly; Ran-GTP–driven spindle assembly (by analogy to TUBB8); chromosome segregation; cell cycle progression through meiosis I/II and early mitosis.

**Protein dysfunction.** Truncation removes the C-terminal region of α-tubulin, producing a non-functional subunit that cannot properly incorporate into microtubules — a **loss-of-function** defect (contrast with dominant-negative TUBB8 missense alleles).

**Molecular profiling.** Single-cell RNA-sequencing of arrested embryos was performed in the index study, supporting the arrest phenotype at the transcriptomic level.

**Suggested ontology terms.**
- **GO (biological process):** GO:0007052 (mitotic spindle organization); GO:0045132 (meiotic chromosome segregation); GO:0007017 (microtubule-based process); GO:0051225 (spindle assembly).
- **GO (cellular component):** GO:0005819 (spindle); GO:0005874 (microtubule); GO:0000922 (spindle pole).
- **CHEBI:** CHEBI:36976 (nucleotide, GTP context of tubulin); CHEBI:15996 (GTP).
- **CL (cell types):** CL:0000023 (oocyte); CL:0000353 (blastomere); CL:0000365 (zygote).

### 7. Anatomical Structures Affected

- **Organ level:** Ovary (germ cells); the affected "unit" is the oocyte and the preimplantation embryo. Reproductive system only; no secondary organ involvement.
- **Tissue/cell level:** **Oocyte (germ cell)**, zygote, and cleavage-stage blastomeres. Somatic tissues are unaffected.
- **Subcellular level:** The **meiotic/mitotic spindle** and **microtubule cytoskeleton**; cytoplasmic tubulin pool.
- **Localization:** Bilateral (both ovaries/all oocytes) — the defect is intrinsic to every germ cell.

**Suggested UBERON terms:** UBERON:0000992 (ovary); UBERON:0000922 (embryo); UBERON:0000995 (uterus — downstream implantation context). Cell level via CL (oocyte CL:0000023).

### 8. Temporal Development

- **Onset:** Functionally congenital (germline defect present from birth) but **clinically manifest at reproductive age** when conception/ART is attempted.
- **Onset pattern:** Chronic/fixed.
- **Progression:** **Stable, non-progressive.** The defect is constant across ART cycles — embryos repeatedly arrest.
- **Disease course:** Lifelong infertility; no remission without donor oocytes.
- **Critical period:** The vulnerable window is oocyte meiotic maturation through the first several embryonic cleavage divisions (the preimplantation period) — the only window where the spindle defect is expressed.

### 9. Inheritance and Population

- **Inheritance pattern:** **Autosomal recessive** (biallelic/homozygous LoF; carriers unaffected) — supported by both the homozygous disease alleles and gnomAD constraint (Finding 2).
- **Penetrance:** Presumed high/complete for the reproductive phenotype in biallelic LoF carriers (based on the small reported cohort).
- **Expressivity:** Variable at the cellular level ("varying degrees of spindle assembly defects").
- **Carrier frequency / founder effects / consanguinity:** Not precisely quantified; consanguinity is the expected context for homozygosity. No founder effect established.
- **Epidemiology:** **Ultra-rare**; precise prevalence/incidence unknown (newly described; identified only in RPEA/infertility cohorts). *Not available.*
- **Sex ratio:** The clinical phenotype is expressed in **females** (oocyte-specific). Male homozygotes would be genotypically affected but the reproductive phenotype is female-limited given TUBA1C's critical role in oogenesis/early embryo.
- **Geographic distribution:** The index cohort was from China; broader distribution unknown.

### 10. Diagnostics

- **Recommended approach:** Molecular genetic testing in women with **recurrent preimplantation embryo arrest / repeated ART failure** and otherwise unexplained infertility.
- **Genetic testing:**
  - **Whole-exome sequencing (WES):** The method by which OZEMA24 was discovered; highest-yield unbiased approach.
  - **Infertility / oocyte-maturation-arrest gene panels:** Should include TUBA1C alongside TUBB8, TUBA4A, PATL2, WEE2, TRIP13, PADI6, and other spindle/meiosis genes.
  - **Single-gene / targeted testing:** Confirmatory Sanger sequencing of TUBA1C variants (NM_032704.5); segregation testing in parents to confirm biallelic inheritance.
  - WGS, CMA, FISH, mtDNA, and repeat-expansion testing are **not specifically indicated** (not a chromosomal or repeat disorder), though karyotype is routine in the general infertility workup.
- **Functional/ancillary:** ART cycle observation documenting the arrest stage; single-cell RNA-seq is a research tool. No specific serum biomarker exists.
- **Clinical criteria:** Diagnosis = clinical RPEA phenotype + biallelic pathogenic TUBA1C variants.
- **Differential diagnosis:** TUBB8-related oocyte maturation arrest (OOMD2), TUBA4A-related RPEA, TRIP13-related arrest, PATL2, WEE2, PADI6, and other oocyte/zygote maturation-arrest genes — distinguished by the specific gene identified on sequencing.
- **Screening:** No population newborn screening (reproductive, non-lethal). Carrier/cascade screening is relevant for relatives of affected consanguineous families.

### 11. Outcome / Prognosis

- **Survival/mortality:** **Not applicable** — OZEMA24 is not life-threatening; it affects fertility only. Normal life expectancy.
- **Morbidity/function:** The sole morbidity is **infertility** and its psychosocial burden; no physical disability.
- **Disease course:** Persistent infertility across natural and ART attempts using the patient's own oocytes; embryos arrest repeatedly.
- **Recovery potential:** No spontaneous recovery; **pregnancy achievable via donor oocytes**.
- **Prognostic factors:** The truncating/LoF nature predicts a consistently severe cellular phenotype. No validated molecular prognostic biomarker beyond the genotype itself.

### 12. Treatment

- **No corrective/curative therapy exists.** Management is supportive and reproductive.
- **Pharmacotherapy:** None specific. Standard ovarian stimulation does not overcome the intrinsic spindle defect.
- **Assisted reproduction:** Because the defect is intrinsic to the patient's oocytes, **donor-oocyte IVF** is the principal route to pregnancy. Standard IVF/ICSI with the patient's own oocytes fails due to recurrent arrest.
- **Experimental/advanced (preclinical):** For the paralogous genes, **cRNA/mRNA rescue** (microinjection of wild-type transcript) restored development in mouse oocytes for certain TUBB8 variants ([PMID: 32949002](https://pubmed.ncbi.nlm.nih.gov/32949002/)), and **HDAC6 inhibition** (Tubacin/Tubastatin A) rescued spindle morphology and polar-body extrusion for a specific TUBB8 missense variant ([PMID: 39834092](https://pubmed.ncbi.nlm.nih.gov/39834092/)). These are **not directly applicable to truncating LoF** of TUBA1C (rescue strategies that augment acetylation/stability are more relevant to missense defects) and remain experimental. Replacement of functional α-tubulin for a complete LoF is unproven clinically.
- **Treatment strategy / personalized medicine:** Genotype-guided counseling; the LoF genotype directs couples toward donor oocytes rather than repeated autologous ART.

**Suggested NCIT terms:** In vitro fertilization (NCIT:C15193); oocyte donation / donor-oocyte IVF; genetic counseling (NCIT:C15336).

### 13. Prevention

- **Primary prevention:** Not applicable (genetic). **Genetic counseling** for consanguineous couples and relatives of affected individuals.
- **Secondary prevention / early detection:** Early genetic testing in women with unexplained infertility or recurrent ART failure to reach diagnosis sooner and avoid repeated futile autologous cycles.
- **Reproductive options:** **Preimplantation genetic testing (PGT)** is of limited value for the affected woman's own oocytes (the arrest precedes testing); the primary clinical issue is the mother's infertility rather than transmitting disease. Carrier couples concerned about offspring genotype could in theory consider PGT-M or donor gametes.
- **Counseling:** Recurrence risk for a carrier × carrier couple is 25% per conception for the genotype; cascade carrier screening for relatives is appropriate.
- **Immunization / public health / environmental interventions:** Not applicable.

### 14. Other Species / Natural Disease

- **Orthologs:** α-tubulin isotypes are deeply conserved. Human TUBA1C has murine orthologs among the Tuba1 gene cluster (e.g., *Tuba1a/Tuba1b/Tuba1c*). Direct TUBA1C-specific natural disease in other species is **not reported**.
- **Natural/veterinary disease:** No OMIA entry for a TUBA1C-specific reproductive arrest disorder was identified. *Not available.*
- **Comparative biology:** The oocyte spindle and its dependence on tubulin isotypes are conserved across mammals; mouse oocytes are the standard model for assaying human tubulin variants (used extensively for TUBB8).
- **Zoonotic/transmission:** Not applicable.

### 15. Model Organisms

- **Mouse oocyte (in vivo/ex vivo):** The dominant model for tubulinopathy-related oocyte arrest. Wild-type and mutant human tubulin mRNA are microinjected into germinal-vesicle–stage mouse oocytes to assay spindle assembly and polar-body extrusion (used for TUBB8: [PMID: 27273344](https://pubmed.ncbi.nlm.nih.gov/27273344/), [PMID: 34509376](https://pubmed.ncbi.nlm.nih.gov/34509376/), [PMID: 32949002](https://pubmed.ncbi.nlm.nih.gov/32949002/)).
- **Cultured cells (HeLa):** Used to assess microtubule network disruption upon expression of mutant tubulin.
- **Knock-in mouse models:** Generated for TUBB8 variants to study meiotic defects ([PMID: 39834092](https://pubmed.ncbi.nlm.nih.gov/39834092/)); an equivalent TUBA1C model is **not yet reported**.
- **Phenotype recapitulation / limitations:** TUBB8 is **primate-specific** in its oocyte-restricted expression, so mouse models imperfectly capture human oocyte biology; for TUBA1C, no dedicated model yet exists. The patients' own arrested embryos (scRNA-seq) provide the most direct human evidence.

---

## Mechanistic Model / Interpretation

OZEMA24 is best understood as an **α-tubulin "tubulinopathy of the oocyte spindle."** The αβ-tubulin heterodimer is the fundamental subunit of microtubules; oocyte meiosis and the earliest embryonic mitoses are exquisitely dependent on a correctly composed, assembly-competent tubulin pool to build a functional spindle. Truncating loss of the TUBA1C α-isotype removes a needed source of α-tubulin, reducing the dimer pool and destabilizing spindle assembly. Because meiosis and the first cleavages are a "closed system" running on maternally supplied components, there is no opportunity for compensatory transcription — so the embryo arrests.

The **recessive, loss-of-function** architecture (Finding 2: tolerated heterozygous LoF, strong missense constraint) distinguishes TUBA1C from the classic **dominant-negative** behavior of many TUBB8 missense variants. The convergence of three independent lines — human WES genetics (Finding 1), population constraint (Finding 2), and functional spindle assays plus the well-mapped TUBB8 paradigm (Finding 3) — makes the causal chain robust. ClinVar/OMIM curation of both alleles as Pathogenic (Finding 4) anchors the clinical interpretation.

| Feature | TUBA1C (OZEMA24) | TUBB8 (OOMD2, paradigm) |
|---|---|---|
| Tubulin class | α-tubulin isotype | β-tubulin isotype (primate-specific, oocyte-restricted) |
| Typical mechanism | Loss of function (truncating) | Often dominant-negative (missense); dimer-pool depletion |
| Inheritance | Autosomal recessive (biallelic) | AD (de novo/dominant) and AR reported |
| Core defect | Spindle assembly defect | ↓αβ dimer, ↓EB1, ↓CKAP5/TACC3, attenuated Ran-GTP |
| Clinical endpoint | RPEA / preimplantation arrest | Oocyte maturation arrest → embryo arrest |
| Rescue demonstrated | Not for LoF | WT cRNA; HDAC6 inhibition (specific missense) |

---

## Evidence Base

| PMID | Title (abbrev.) | Role in this report |
|---|---|---|
| [39209701](https://pubmed.ncbi.nlm.nih.gov/39209701/) | *Biallelic variants in α-tubulin isotypes cause female infertility characterised as recurrent preimplantation embryo arrest* | **Primary/defining paper** — identifies TUBA1C p.Gln358Ter and p.Asp444Metfs\*42 as causal; establishes spindle-defect mechanism and RPEA endpoint (Findings 1 & 3). |
| [39834092](https://pubmed.ncbi.nlm.nih.gov/39834092/) | *Pathogenic variants of TUBB8 cause oocyte spindle defects by disrupting EB1/CKAP5 interactions…HDAC6 inhibition* | Mechanistic paradigm for tubulin-isotype spindle failure (EB1, CKAP5/TACC3, Ran-GTP); experimental rescue (Finding 3). |
| [39030352](https://pubmed.ncbi.nlm.nih.gov/39030352/) | *Predicting Infertility: How Genetic Variants in Oocyte Spindle Genes Affect Egg Quality* | Review contextualizing spindle-gene variants (TUBB8, TACC3, AURKA, etc.) and their fertility consequences. |
| [32473092](https://pubmed.ncbi.nlm.nih.gov/32473092/) | *Bi-allelic Missense Variants in TRIP13 Cause…Oocyte Maturation Arrest* | Differential-diagnosis gene; recessive oocyte-arrest precedent; cRNA rescue precedent. |
| [32949002](https://pubmed.ncbi.nlm.nih.gov/32949002/) | *Identification and rescue of a novel TUBB8 mutation that causes first mitotic division defects* | Demonstrates abnormal spindle + WT-cRNA rescue in mouse oocytes (experimental-therapy context). |
| [27273344](https://pubmed.ncbi.nlm.nih.gov/27273344/) | *Mutations in TUBB8 cause a multiplicity of phenotypes in human oocytes and early embryos* | Establishes the tubulinopathy framework; variable penetrance/expressivity; folding/microtubule defects. |
| [34509376](https://pubmed.ncbi.nlm.nih.gov/34509376/) | *Two mutations in TUBB8 cause developmental arrest in human oocytes and early embryos* | Recessive TUBB8 precedent (p.A54V) and fertilization-then-fragmentation phenotype. |

**Evidence-type distribution:** 1 defining human-clinical+functional study for TUBA1C; multiple human-clinical + mouse-oocyte + in-vitro studies for the TUBB8/TRIP13 paradigm; 1 computational (gnomAD) constraint analysis; curated databases (ClinVar/OMIM).

---

## Limitations and Knowledge Gaps

1. **Single defining study / very few patients.** OZEMA24 rests on one cohort (Hu et al. 2024) with two homozygous TUBA1C alleles. Penetrance, expressivity, carrier frequency, and prevalence are therefore essentially **unquantified**.
2. **No TUBA1C-specific animal model.** Mechanistic detail (EB1, CKAP5/TACC3, Ran-GTP) is **inferred from TUBB8**, not yet directly demonstrated for TUBA1C. The obligate-heterodimer logic is strong but formally extrapolated.
3. **No disease-specific Orphanet/ICD/MeSH codes** were located; identifiers remain at the gene/OMIM/MONDO level.
4. **No epidemiology** (prevalence/incidence/geographic distribution) — only that the index cohort was Chinese.
5. **Therapeutic uncertainty.** Rescue strategies validated for TUBB8 missense variants (WT cRNA, HDAC6 inhibition) are **not established for complete LoF** of TUBA1C and are preclinical.
6. **NMD vs. truncated-protein question.** Whether the truncating alleles act via nonsense-mediated decay (null) or a residual truncated protein with partial dominant-negative activity has not been dissected.

---

## Proposed Follow-up Experiments / Actions

1. **Expand the patient cohort** via GeneMatcher / multicenter RPEA registries to identify additional TUBA1C biallelic cases and refine penetrance and the allelic spectrum.
2. **Generate a TUBA1C model**: mouse-oocyte mRNA knock-in/knockdown and/or TUBA1C-null human oocyte/organoid systems to directly test spindle assembly, EB1/CKAP5-TACC3 recruitment, and Ran-GTP dynamics.
3. **Determine the molecular fate of truncating alleles** (NMD vs. truncated protein) by allele-specific expression and immunoblot in patient cells.
4. **Test rescue feasibility**: microinjection of wild-type TUBA1C cRNA into affected oocytes (as done for TUBB8/TRIP13) to assess whether functional α-tubulin restores spindle formation — a prerequisite for any future therapeutic concept.
5. **Curate/register identifiers**: obtain dedicated Orphanet cross-references and ensure TUBA1C is added to clinical infertility gene panels.
6. **Carrier screening study** in consanguineous populations to estimate carrier frequency and possible founder effects.

---

*Report compiled from 4 confirmed findings and 7 reviewed papers across 5 investigation iterations. Causal gene: **TUBA1C**. Primary reference: Hu et al., J Med Genet 2024, PMID 39209701.*


## Artifacts

- [OpenScientist final report](Oocyte_Zygote_Embryo_Maturation_Arrest_24-deep-research-openscientist_artifacts/final_report.html)
- [OpenScientist final report](Oocyte_Zygote_Embryo_Maturation_Arrest_24-deep-research-openscientist_artifacts/final_report.pdf)

## Reference Validation

Checked with `linkml-reference-validator` 0.4.0.

| Outcome | Count |
| --- | --- |
| References checked | 7 |
| Resolved | 7 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 7 |
| On topic | 7 |
| Off topic | 0 |

All extracted references resolved successfully.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 22 |
| Resolved | 20 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 0 |
| Unverifiable | 2 |
| Terms whose name was checked | 17 |
| Terms named correctly | 12 |
| Terms named as a **different** term | 3 |
| Terms whose name is worth a second look | 2 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `HP:0030359` (1 mention) - the report calls it "Abnormality of female reproductive system"; HP calls it **Squamous cell lung carcinoma**
- `CHEBI:36976` (1 mention) - the report calls it "nucleotide, GTP context of tubulin"; CHEBI calls it **nucleotide**
- `UBERON:0000995` (1 mention) - the report calls it "uterus — downstream implantation context"; UBERON calls it **uterus**

### Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a *related* synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

- `CL:0000353` (1 mention) - the report calls it "blastomere"; CL calls it **blastoderm cell**, and lists "blastomere" among its other names
- `CL:0000365` (1 mention) - the report calls it "zygote"; CL calls it **animal zygote**, and lists "zygote" among its other names

### Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: `OMIM`.